Composur, A Patient-centric,Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient TreatmentSatisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder

Medicine & Life Sciences

1. N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide 100%
2. Overactive Urinary Bladder 54%
3. Quality of Health Care 38%
4. Quality of Life 28%
5. Patient Satisfaction 20%